Tarsus Pharmaceuticals, Inc. (TARS)
68.20
-3.88
(-5.38%)
USD |
NASDAQ |
Oct 23, 16:00
68.16
-0.04
(-0.06%)
After-Hours: 20:00
Tarsus Pharmaceuticals Gross Profit Margin (Quarterly) : 93.04% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 93.04% |
| March 31, 2026 | 94.20% |
| December 31, 2025 | 92.80% |
| September 30, 2025 | 93.00% |
| June 30, 2025 | 93.92% |
| March 31, 2025 | 93.35% |
| December 31, 2024 | 92.58% |
| September 30, 2024 | 93.26% |
| June 30, 2024 | 92.64% |
| March 31, 2024 | 94.01% |
| December 31, 2023 | 90.70% |
| Date | Value |
|---|---|
| September 30, 2023 | 60.13% |
| June 30, 2023 | |
| March 31, 2023 | 89.80% |
| December 31, 2022 | 96.00% |
| September 30, 2022 | |
| June 30, 2022 | 96.58% |
| March 31, 2022 | 65.31% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 85.40% |
| June 30, 2021 | 96.65% |
| March 31, 2021 | 96.12% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 67.95% |
| Amneal Pharmaceuticals, Inc. | 42.01% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -13.61% |
| Return on Assets | -8.33% |
| Return on Invested Capital | -10.95% |
| Profit Margin (Quarterly) | -10.67% |
| Operating Margin (Quarterly) | -11.45% |
| Return on Net Operating Assets | -34.68% |